U.S. market Open. Closes in 24 minutes

BBLG | Bone Biologics Corporation Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for BBLG we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak.

Valuation (14%)

Company Industry
P/E Ratio (TTM) -0.39 48.02
PEG Ratio (TTM) -0.01 -0.83
P/S Ratio (TTM) N/A 6.15
P/B Ratio (TTM) 0.69 6.12
P/FCF Ratio (TTM) -0.54 42.36
Price to 5YR AVG Earnings Ratio -0.02 60.05
Price to 5YR AVG FCF Ratio -1.01 34.49

Profitability (25%)

Company Industry
ROA (TTM) -160.31% 5.35%
ROE (TTM) -154.16% 28.08%
Net Profit Margin (TTM) N/A 7.83%
ROIC 5YR AVG 401.33% 6.72%

Growth (33%)

4QTR AVG 3YR AVG 5YR AVG
EPS 52.06% -78.74% -90.36%
Revenue N/A N/A N/A
Net Income 16.10% 27.05% -232.30%
Cash Flow 29.34% -26.70% -87.67%

Health (30%)

Company Industry
Current Ratio (TTM) 11.22 2.87
Quick Ratio (TTM) 11.22 2.15
D/E Ratio (TTM) N/A 0.62
Interest Coverage (TTM) 8.81 22.95
Piotroski F-Score 1 6
Altman Z-Score N/A 7.63
LTL to 5YR AVG FCF N/A 3.49
Shares Outstanding Growth 5YR AVG 115.61% 1.63%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙